You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Oxygen Production and Delivery on Demand
SBC: GLOBAL RESEARCH & DEVELOPMENT INC Topic: DHA17B005This proposal is in response to the Defense Health Agency 2017 Phase I SBIR topic 17B-005.The approach is the use of a membrane oxygen pump using newly developed nano-thickness membranes with all the layers less than 1 micron total.Nanometer thickness membranes enable more oxygen output per surface area at temperatures of 300-600 C than current state-of-the -art 600-800 C membranes that are 50-300 ...
STTR Phase I 2018 Department of DefenseDefense Health Agency -
Inhibiting Prolyl Hydroxylase to Mimic Natural Acclimatization to High Altitude to Improve Warfighter Performance at High Altitude
SBC: Research Logistics Company Topic: SOCOM17C001Acclimatization is the long-term adjustment that humans experience when exposed for weeks or months to high altitude. Acclimatization is important in this context because a warfighter who is acclimatized to high altitude is immune to high altitude illness, has superior work capacity, and has cognitive function approaching that found at sea level. In other words, the acclimatized warfighter is opti ...
STTR Phase I 2018 Department of DefenseSpecial Operations Command -
System for Nighttime and Low-Light Face Recognition
SBC: MUKH Technologies LLC Topic: SOCOM18A001Recognizing faces in low-light and nighttime conditions is a challenging problem due to the noisy and poor quality nature of the images.Thermal imaging is often used to obtain facial biometric in such conditions. Thermal face images, while having a strong signature at nighttime, are not typically maintained in biometric-enabled watch lists and so must be compared with visible-light face images to ...
STTR Phase I 2018 Department of DefenseSpecial Operations Command -
Small Team Command, Control, Communications and Situational Awareness (C3SA), SOCOM08-001
SBC: CEEBUS TECHNOLOGIES, LLC Topic: SOCOM08001SOF combat swimmers have a need for the continuous monitoring of each others relative position while diving and for the capability of being able to communicate with each other to help establish a common operational picture (COP).The C3SA system was previously developed under SBIR Topic SOCOM08-001 thru the receipt of both Phase I and Phase II SBIR awards.The C3SA established a stand-alone network ...
STTR Phase II 2018 Department of DefenseSpecial Operations Command -
An Engineered Nanoimmunotherapy for Melanoma
SBC: IMMUNOBLUE, LLC Topic: NCIPROJECT SUMMARY Melanoma is one of the most prevalent cancers and is estimated to account for overdeaths inin the United States aloneAlthough highly curable when detected earlytheyear survival rates decline precipitously for patients with regionaland metastaticmelanoma indicating a lack of efficacy of conventional therapiesand a strong need for novel therapies for this patient populationIn respons ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Building an evidentiary case for circulating GHBP as a biomarker for drug-associated stunting of growth
SBC: REVERAGEN BIOPHARMA, INC. Topic: NICHDThere is increasing interest in the use of biomarkers in clinical drug developmentwith much of thest Century Cures Act focused on encouraging this approachIdeallybiomarkers could provide and acute and objective read out of drug mechanism of actionpharmacodynamic biomarkersor prediction of later clinical benefit or harmsurrogate outcome measureHoweververy few biomarkers have been validated for rout ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
A universal eye drop adherence monitor to measure and improve adherence to ocular medications
SBC: Universal Adherence LLC Topic: NProject Summary Abstract Universal Adherence is an emerging medical device company dedicated to improving adherence to ocular medications through innovative technical solutionsOur proposed Devers Drop DeviceDwill accurately track when a patient removes an eye drop bottle capcommunicate usage data wirelessly to a database that researchers can accessand send alerts to patients when a medication is d ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Noninvasive placement and activation of deep-brain stimulating magnetic particles for reduction of drug-seeking behaviors
SBC: WEINBERG MEDICAL PHYSICS, INC. Topic: NIDAAbstract Deep brain stimulationDBSwith implantable electrodes has been used for reduction of ethanol abuse and drug seeking behaviors in EuropeThe use of such deep brain stimulation procedures has been problematic because of concerns about invasiveness of the procedureApplicant has developed a new noninvasive method of transporting magnetic particles directly to target sites within the brainWe pro ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Expansion of Immuno-CometChip Platform
SBC: AMELIA TECHNOLOGIES LLC Topic: NIEHSProject SummaryThe objective of this supplementation request is to further our recent advances in the development of thewell Immuno CometChip assay results and build a prototypewell preformer giving the assay more utility and increasing commercial viability
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
TFEB Activator for Alzheimer's Disease Therapy
SBC: BRILLIANT BIOSCIENCES INC. Topic: NIAOne in ten of the persons ageare affected by Alzheimer s diseaseADcausing enormous social and economic burden to the United StatesTo date only five medications have been approved by the FDA for the treatment of the symptoms of ADbut none of them slows or stops the disease progressionWith the recent repeated failures of AD drugs on thesecretase inhibitorsthe need for an effective AD drug became eve ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health